AP 002 - ArrePath
Alternative Names: AP-002- ArrePathLatest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator ArrePath
- Class Anti-infectives; Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacteraemia; Intra-abdominal infections; Nosocomial infections; Urinary tract infections
Most Recent Events
- 18 Oct 2024 Preclinical trials in Bacteraemia in USA (IV) (ArrePath pipeline, October 2024)
- 18 Oct 2024 Preclinical trials in Bacteraemia in USA (PO) (ArrePath pipeline, October 2024)
- 18 Oct 2024 Preclinical trials in Intra-abdominal infections in USA (IV) (ArrePath pipeline, October 2024)